Potential Benefits. 1. Opioids (morphine-like substances) are more effective in the treatment of acute pain than chronic pain. While opioids can at times abolish acute pain, the expected reduction of chronic pain is only about 20% at the beginning of the treatment period.
Potential Benefits. Potential benefits include improvement in the study participant’s lung function and other improvements that may be associated with improved lung function.
Potential Benefits. Potential benefits you may experience as a participant in the study include having improved lung function and other improvements that may be associated with improved lung function, such as improved quality of life. If it is determined that control group participants still meet study eligibility criteria and it seems clinically appropriate for them after their 1-year follow-up visit, the study sponsor will pay for these participants to undergo the EBV and bronchoscopy procedure. Potential Risks The primary risks associated with use of the Pulmonx EBV are similar to other bronchoscopic and surgical procedures used to treat emphysema. These are listed below. While this list is comprehensive, there may be other risks that are still unknown. The close monitoring that you will receive, as part of the study, should allow for detection of symptoms, should they be present. This, in turn, should allow for early intervention by your physician if that is necessary. Your physician will review all of the risks below with you so that you understand them. Previous clinical trial experience and experience from other countries around the world, where the EBV device is commercially available, has shown that in some people EBV treatment is associated with having a pneumothorax as a potential complication. A pneumothorax is a condition in which air leaks from the lung into the space between the lung and chest wall. This prevents the healthy lung from working well and can cause chest pain and shortness of breath. As many as 1 in 5 patients may experience a pneumothorax after the study procedure. Most of these tend to occur in the early period following the valve placement and usually resolve after staying in hospital for a few days. Most frequently, a treatment using a small tube to drain out the air is required. In rare cases, a pneumothorax may require a surgical intervention. In addition, there is a chance that it can be a serious and life- threatening complication. Potential Risks (Adverse Events) Acute bronchitis (inflammation or infection of the airways) Acute bronchospasm (spasm of the airway; may result in wheezing or increased shortness of breath) Acute respiratory distress syndrome (sudden, severe injury to lungs) Airway blockage due to implant migration Airway perforation (hole in the airway wall) Airway stenosis (narrowing) Anxiety Aphonia (difficulty talking) Aspiration (inhalation of vomit) Bowel function impairment Bronchial (airway) trauma or ulceration Chest pa...
Potential Benefits. The benefit of sharing this information will be improved support to those affected by cuckooing; leading to reduced risk, increased safety, health and well being of adults
Potential Benefits. This cumulative data will be used as baseline information to partially assess the effectiveness of efforts to reduce the pollutant load to the wastewater collection system and measures designed to protect the watershed. Other anticipated benefits include a potential reduction of the concentration of toxic metals in the “Dyno Dirt” class AAA composted biosolids produced at the Pecan Creek Water Reclamation Plant. The potential reduction of metals concentrations in the compost will be assessed in relation to the accumulated baseline data.All of these benefits depend upon the City’s ability to allocate resources to maximize effort and minimize economic burden. The City of Xxxxxx firmly believes that with minor enhancement of our current organizational structure, a watershed protection program can be developed that will meet the intent of the Clean Water Act at a cost acceptable to rate payers.
Potential Benefits. The subject may or may not benefit from this study. Although CBBCT device has been approved by the FDA, the use of contrast agent in CBBCT scan has not received FDA approval. If unusual/unexpected findings are noted only in CE-CBBCT, the patient will be referred for further workups. It is possible, though not probable, that the patient may have important breast problems identified because of the additional imaging she undergoes with CE-CBBCT.
Potential Benefits. As this study is intended to monitor the long-term safety following the administration of NI-0501, as well as the impact on survival, the main benefit for the patient is to be closely monitored, enabling the early detection of a potential issue. However, in case the patient would continue to receive NI-0501 in the context of this study after having successfully completed the NI-0501-04 protocol, the expected benefit is to maintain the therapeutic effects of NI-0501 treatment, enabling transplantation to be performed without using immune chemotherapy that has short and long term risks.
Potential Benefits. The efficacy of VTX-2337 has not been formally evaluated in clinical trials to date. However, exploratory data from study VRXP-A101 showed 25% of the 33 subjects enrolled had disease stabilization at 8 weeks. In addition, preliminary data from a phase 1b study of VTX-2337 in combination with cetuximab in patients with advanced SCCHN (n=10) included 1 subject who experienced a partial response, 2 subjects who experienced disease stabilization; two subjects were not evaluable and 2 subjects have not yet had a tumor evaluation. Furthermore, a phase 1b study of VTX-2337 with chemotherapy in women with recurrent, platinum-resistant ovarian cancer (n=20) included 2 subjects who experienced complete response (one of which was a biochemical CR) and 10 subjects who experienced disease stabilization (2–8 months). The current study of VTX-2337 is a multi-dose study to assess the safety, tolerability and efficacy of the investigational drug in combination with cisplatin or carboplatin, 5-FU, and cetuximab. The clinical efficacy of this combination has not yet been evaluated; however, the addition of VTX-2337 to the standard-of-care (SOC) treatment regimen may be more effective than SOC alone. Participating subjects may also benefit from the personal satisfaction of participating in an investigative process that will contribute information regarding the investigational product (IP) that may help patients afflicted with SCCHN.
Potential Benefits. The efficacy of VTX-2337 has not been formally evaluated in clinical trials to date. However, exploratory data from study VRXP-A101 showed 25% of the 33 subjects enrolled had disease stabilization at 8 weeks. In addition, preliminary data from a phase 1b study of VTX-2337 in combination with cetuximab in patients with advanced SCCHN (n=13) included 2 subjects who experienced a partial response, 4 subjects who experienced disease stabilization; 2 subjects were not evaluable and 1 subject has not yet had a tumor evaluation. Furthermore, a phase 1b study of VTX-2337 with chemotherapy in women with recurrent, platinum-resistant ovarian cancer (n=20) included 2 subjects who experienced complete response (one of which was a biochemical CR), 1 subject who experienced a partial response, and 10 subjects who experienced disease stabilization (2–8 months). The current study of VTX-2337 described herein is a multi-dose study to assess the safety, tolerability and efficacy of the investigational drug in combination with cisplatin or carboplatin, 5-FU, and cetuximab. The clinical efficacy of this combination has not yet been evaluated; however, the addition of VTX-2337 to the standard-of-care (SOC) treatment regimen may be more effective than SOC alone. Participating subjects may also benefit from the personal satisfaction of participating in an investigative process that will contribute information regarding the investigational product (IP) that may help patients afflicted with SCCHN.
Potential Benefits. Participants may benefit from knowing how much time they spend on Instagram as well as the way Instagram affects their mood. The research may provide information about the benefits to not using Instagram before class as it may result in memory implications.
